Drug Combination Details
General Information of the Combination (ID: C50594) | |||||
---|---|---|---|---|---|
Name | Anisodamine NP Info | + | Neostigmine Drug Info | ||
Structure |
![]() |
+ |
![]() |
||
Disease |
Rheumatoid arthritis
[ICD-11: FA20]
|
Investigative | [1] | ||
Ischemic stroke
[ICD-11: 8B11]
|
Investigative | [2] | |||
Lethal crush syndrome
[ICD-11: NF0A]
|
Investigative | [3] |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. Enhancing Drug Efficacy by This Combination | ||||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Experiment 1 Reporting the Effect of This Combination | [2] | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | BAD | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
In-vivo Model | Male Sprague-Dawley rats were used in this study. | |||||
Experimental
Result(s) |
Current study identified the optimal combination of neostigmine and anisodamine against ischemic stroke, and indicated that the acetylcholine-Alpha7 nicotinic acetylcholine receptor is involved in the protective effects. | |||||
Experiment 2 Reporting the Effect of This Combination | [3] | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | JAK-2 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | STAT3 | Molecule Info |
Pathway MAP
|
||
In-vivo Model | SD rats (250-270 g), C57BL/6 mice (25-30 g), and rabbits (2-3 kg) CS models were used in this study. | |||||
Experimental
Result(s) |
Ani/Neo combination could produce therapeutic effects in CS. | |||||
Experiment 3 Reporting the Effect of This Combination | [1] | |||||
In-vivo Model | CIA was induced in DBA/1 mice which were immunized with 100 ug bovine type II collagen and emulsified with an equal volume of complete Freund's adjuvant. | |||||
Experimental
Result(s) |
A combination of anisodamine and neostigmine could decrease arthritic index, reduce joint swelling, and inhibit weight loss. |




